Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, double-blind, placebo-controlled, phase IIa study
Date: 2022-11-14 Authors: Bissonnette R, Abramovits W, Saint-Cyr Proulx Ă, Lee P, Guttman-Yassky E, Zovko E, Sigmund R, Willcox J, Bieber T Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases
Date: 2022-09-30 Authors: Pavel AB, Del Duca E, Cheng J, Wu J, Ungar B, Estrada YD, Jack C, Maari C, Saint-Cyr Proulx Ă, Ramirez-Valle F, Krueger JG, Bissonnette R, Guttman-Yassky E Category: Other Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis
Date: 2022-09-12 Authors: Reich K, Lio PA, Bissonnette R, Alexis AF, Lebwohl MG, Pink AE, Kabashima K, Boguniewicz M, Nowicki RJ, Valdez H, Zhang F, DiBonaventura M, Cameron MC, Clibborn C Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more […]
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
Date: 2022-08-07 Authors: Gooderham MJ, Girolomoni G, Moore JO, Silverberg JI, Bissonnette R, Forman S, Peeva E, Biswas P, Valdez H, Chan G Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non-Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular Psoriasis
Date: 2022-08-04 Authors: Wang CQ, Haxhinasto S, Garcet S, Kunjravia N, Cueto I, Gonzalez J, Rambhia D, Harari O, Sleeman MA, Hamilton JD, Lim WK, Freudenberg J, Kalliolias GD, Thakker P, Bissonnette R, Krueger JG Category: Psoriasis Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). […]
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis
Date: 2022-07-11 Authors: Berdyshev E, Goleva E, Bissonnette R, Bronova I, Bronoff AS, Richers BN, Garcia S, Ramirez-Gama M, Taylor P, Praestgaard A, Agueusop I, Jurvilliers P, Boguniewicz M, Levit NA, Rossi AB, Zhang A, Leung DYM Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix […]
Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials
Date: 2022-07-01 Authors: Wollenberg A, Lio P, Kleyn E, Bissonnette R, Jose Rueda M, Casillas M, Chen YF, Lu N, Schloebe A, Simpson E Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
One-Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial
Date: 2022-06-27 Authors: Strober B, Stein Gold L, Bissonnette R, Armstrong AW, Kircik L, Tyring SK, Piscitelli SC, Brown PM, Rubenstein DS, Tallman AM, Lebwohl MG.J Category: Psoriasis Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
Date: 2022-05-23 Authors: Bissonnette R, Call RS, Raoof T, Zhu Z, Yeleswaram S, Gong X, Lee M Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read more on pubmed
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Date: 2022-05-03 Authors: Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo SJ, Khokhar FA, Vakil J, Xiao J, Marco AR, Levit NA, O’Malley JT, Shabbir A Category: Dermatitis (all types) Conflict of interest statement: Conflicts of interest The full list is provided in Appendix S1 (see Supporting Information). Read […]
